Stay updated on Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.

Latest updates to the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to include a new vulnerability disclosure section and has revised its version number to v2.16.8, while removing outdated dates and the previous version number v2.16.6.SummaryDifference1%
- Check11 days agoChange DetectedThe web page has been updated from version 2.16.5 to version 2.16.6.SummaryDifference0.6%
- Check18 days agoChange DetectedA service alert has been added indicating planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.SummaryDifference0.7%
- Check25 days agoChange DetectedThe page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.SummaryDifference0.7%
- Check32 days agoChange DetectedThe ClinicalTrials.gov data ingest modernization has been rescheduled to July 2025, and the study GLORIOSA has been updated with new details regarding its design and locations, including a significant increase in the number of participating sites.SummaryDifference100%
- Check47 days agoChange DetectedThe web page has been updated from version v2.16.2 to v2.16.3.SummaryDifference0.4%
Stay in the know with updates to Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.